Mepolizumab for eosinophilic chronic obstructive pulmonary disease Authors: Pavord ID, Chanez P, Criner GJ, et al. N Engl J Med 2017; 377: 1613 -1629 . Summary: Eosinophilic chronic obstructive pulmonary disease (COPD) is characterised by a peripheral blood differential eosinophil count of 2% or more. This phenotype is found in roughly 40% of patients with COPD. These patients have an increased frequency of exacerbations, but benefit from inhaled glucocorticoids as part of a triple therapy regime. However, 30-40% of these patients continue to have significant exacerbations, meaning targeted therapy to reduce eosinophil counts could play a role in future therapy. Mepolizumab blocks interleukin-5 and has been associated with a decreased rate of exacerbation in eosinophilic asthma.
Pavord et al. conducted two, phase 3, randomised, placebo-controlled, double-blind, parallel group trials in 16 and 15 countries, respectively: mepolizumab versus placebo as add-on treatment for frequently exacerbating COPD patients (METREX); and mepolizumab versus placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level (METREO). Mepolizumab was given as a subcutaneous injection every 4 weeks over 1 year alongside regular inhaled triple therapy. The main end-point measured was annual rate of moderate or severe exacerbations. METREX studied the use of 100 mg and METREO the use of 100 mg and 300 mg, versus placebo.
In the METREX study, there was a statistically significant reduction in the modified intention-totreat population with an eosinophilic phenotype. METREO also showed significance, but only in the 100 mg group. A higher eosinophil count at screening was associated with improved outcomes. Mepolizumab was also shown to have a similar safety profile as the placebo.
These studies concluded that among patients with an eosinophilic COPD phenotype who still have exacerbations despite maximal triple therapy the 100 mg regimen of mepolizumab reduced the rate of exacerbation over placebo. This study rigorously analyses the use of mepolizumab and suggests it offers significant benefit to patients. If this is the case, then we are closer to tailoring treatment for patients with eosinophilic COPD and reducing morbidity and mortality in this group. Summary: It is now a widely accepted fact that exposure to various materials in the workplace may contribute to the development of allergic rhinitis. Apart from the livelihood of the workers, the recurrent episodes may also significantly impair work productivity. However, the association between disease prevalence and work productivity has remained unclear.
To further address this question, Vandenplas et al. undertook a rigorous statistical approach to make a quantitative estimate of the impact of allergic rhinitis on work productivity. In this systematic review, they analysed the results of studies published between 2005 and 2015 which addressed the impact of allergic rhinitis on work productivity. 30 studies were included, all of which used the Work Productivity and Activity ImpairmentAllergy Specific instrument for estimating the magnitude of the work productivity impairment related to allergic rhinitis.
From the pooled data analyses, the authors found an estimated 3.6% of patients (95% confidence interval: 2.4-4.8%) missed work time due to allergic rhinitis whereas 35.9% (95% CI: 29.7-42.1%) had impaired at-work performance. The pooled analysis also underscored an estimated 39.4% (95% CI: 34.8-44.0%) loss of work-productivity as a result of allergic rhinitis. The severity of allergic rhinitis symptoms was found to be the most consistent disease-related risk factor which could substantially alter work productivity. The authors identified that pharmacological treatment of allergic rhinitis could reverse the impact on work productivity. One of the reports included in this systematic review found a mean reduced work impairment among workers with allergic rhinitis who received levocetrizine (mean work impairment, days per month: 0.7; 95% CI: 0.5-0.9) than among those who received placebo (1.0; 95% CI: 0.8-1.3) (Bousquet et al. Int Arch Allergy Immunol 2009; 150: 75-82) .
This systematic review provides, for the first time, an effective estimate of the impact of allergic rhinitis on work productivity along with a clearer indication of the principal contributing factors which will help physicians and policy-makers to devise an effective strategy for a better work environment. 198 patients from 14 US medical centres were screened over a period of more than 3 years and 142 were deemed eligible and randomised: 73 in the CYC arm and 69 in the MMF arm. Baseline characteristics for both groups were comparable, with no statistically significant differences between the two groups. Participants had an average age of 52 years and were predominantly women (73.9%); mean forced vital capacity (FVC) was 66.5% predicted and mean diffusing capacity of the lungs for carbon monoxide was 54% predicted among participants. No significant difference was found between the two treatment groups in the course of FVC % predicted over the entire 24 months of the study, and MMF treatment was therefore not found to be superior in efficacy compared with oral CYC. However, both treatments produced improvements in lung function, dyspnoea and modified Rodnan score, a score which evaluates patient's skin thickness, compared with baseline.
Overall, MMF appears to be better tolerated than CYC, with a good safety profile based on the number of treatment failures and patient withdrawal, and this is the first study showing efficacy of MMF in symptomatic patients with SSc-ILD. Evidently, physicians can now use both immunosuppressants for this group of patients and MMF appears to be less cytotoxic and at least as effective as CYC. Reviewed by: Alexis Papadopoulos (UK,
